Bridge Biotherapeutics Stock Last Dividend Paid
| 288330 Stock | KRW 4,495 555.00 14.09% |
Bridge Biotherapeutics fundamentals help investors to digest information that contributes to Bridge Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Bridge Stock. The fundamental analysis module provides a way to measure Bridge Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bridge Biotherapeutics stock.
Bridge |
Bridge Biotherapeutics Company Last Dividend Paid Analysis
Bridge Biotherapeutics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, Bridge Biotherapeutics has a Last Dividend Paid of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology & Medical Research (which currently averages 0.0) industry. This indicator is about the same for all Republic of Korea stocks average (which is currently at 0.0).
Did you try this?
Run Price Exposure Probability Now
Price Exposure ProbabilityAnalyze equity upside and downside potential for a given time horizon across multiple markets |
| All Next | Launch Module |
Bridge Fundamentals
| Return On Equity | -75.4 | |||
| Current Valuation | 29.26 B | |||
| Shares Owned By Insiders | 30.27 % | |||
| Shares Owned By Institutions | 9.09 % | |||
| Revenue | 1.92 B | |||
| Gross Profit | (1.12 B) | |||
| EBITDA | (21.27 B) | |||
| Net Income | (26.28 B) | |||
| Cash And Equivalents | 8.2 B | |||
| Total Debt | 53.63 M | |||
| Current Ratio | 1.05 X | |||
| Cash Flow From Operations | (21.13 B) | |||
| Market Capitalization | 217.07 B | |||
| Total Asset | 46.66 B | |||
| Net Asset | 46.66 B |
About Bridge Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bridge Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bridge Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bridge Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bridge Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bridge Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bridge Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bridge Stock
Moving against Bridge Stock
| 0.58 | 035420 | Naver | PairCorr |
| 0.56 | 032640 | LG Uplus | PairCorr |
| 0.55 | 041510 | SM Entertainment | PairCorr |
| 0.39 | 078160 | MEDIPOST | PairCorr |
| 0.38 | 011390 | Busan Industrial | PairCorr |
The ability to find closely correlated positions to Bridge Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bridge Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bridge Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bridge Biotherapeutics to buy it.
The correlation of Bridge Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bridge Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bridge Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bridge Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Bridge Stock
Bridge Biotherapeutics financial ratios help investors to determine whether Bridge Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bridge with respect to the benefits of owning Bridge Biotherapeutics security.